Update shared on16 Aug 2025
Fair value Decreased 7.69%The consensus price target for Lifeward has been revised down to $8.00, primarily reflecting a sharp decrease in its future P/E multiple, while profitability remains stable.
What's in the News
- Lifeward reset full-year 2025 earnings guidance under new management, targeting revenue of $24–$26 million.
- Reported $2.78 million in impairment charges for Q2 2025.
- Almog Adar appointed CFO, succeeding Michael Lawless, who resigned for personal reasons; Adar previously served as VP of Finance and Chief Accounting Officer.
- Received Nasdaq deficiency notice for failing to maintain $1.00 minimum bid price; has 180 days to regain compliance or risk delisting.
- Expanded distribution agreement with SportsMed Products Ltd., extending AlterG product distribution to the UAE and entire GCC region.
Valuation Changes
Summary of Valuation Changes for Lifeward
- The Consensus Analyst Price Target has fallen from $8.67 to $8.00.
- The Future P/E for Lifeward has significantly fallen from 14.95x to 9.40x.
- The Net Profit Margin for Lifeward remained effectively unchanged, moving only marginally from 14.75% to 14.82%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.